GO:0160145 negative regulation of GDF15-GFRAL signaling pathway

The GDF15-GFRAL signaling pathway is a critical endocrine axis that links cellular stress to systemic metabolic adaptation. GDF15, a member of the TGF-beta superfamily, is secreted in response to various stressors including mitochondrial dysfunction, inflammation, and cancer. Its receptor, GFRAL (GDNF family receptor alpha-like), is expressed almost exclusively in the area postrema and nucleus of the solitary tract of the hindbrain, where it mediates appetite suppression and weight loss. The biological process GO:0160145, negative regulation of GDF15-GFRAL signaling pathway, encompasses all molecular events that attenuate this signaling cascade, thereby modulating food intake and energy homeostasis. Understanding how this pathway is negatively regulated is of paramount importance because excessive GDF15-GFRAL activity contributes to cachexia, a debilitating wasting syndrome associated with cancer and chronic diseases. Conversely, insufficient negative regulation may exacerbate metabolic dysfunction. Recent studies have identified proteolytic cleavage of GFRAL by MT1-MMP as a key negative regulatory mechanism, reducing receptor availability and dampening GDF15 responsiveness. Additionally, nanobody-mediated sequestration of GDF15 has emerged as a therapeutic strategy to block pathway activity and restore body weight in cachexia models. For researchers, GO:0160145 provides a conceptual framework to investigate the molecular brakes on this pathway. By employing CRISPR gene editing to create knockout, point-mutation, and knock-in models, scientists can pinpoint the exact genes and mechanisms that negatively regulate GDF15-GFRAL signaling. This knowledge is essential for developing targeted therapies for cachexia, amyotrophic lateral sclerosis, and other metabolic disorders.

GO:0160145, negative regulation of GDF15-GFRAL signaling pathway, is a biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of GDF15-GFRAL signaling. In practical terms, it includes mechanisms such as proteolytic cleavage of the GFRAL receptor, sequestration of the GDF15 ligand, downregulation of receptor expression, and inhibition of downstream intracellular signaling events that would otherwise lead to reduced food intake and weight loss.

Negative regulation of GDF15-GFRAL signaling is a pivotal control point in energy homeostasis and disease. Excessive pathway activity drives pathological weight loss in cancer cachexia and amyotrophic lateral sclerosis, while insufficient activity may contribute to obesity and metabolic syndrome. Elucidating the negative regulatory mechanisms, such as MT1-MMP-mediated GFRAL cleavage, offers opportunities for therapeutic intervention. Moreover, the pathway's unique expression pattern and systemic effects make it an attractive target for CRISPR-based functional genomics and drug development.

The following genes and proteins are central to the negative regulation of GDF15-GFRAL signaling, based on verified literature.

The negative regulation of GDF15-GFRAL signaling is itself subject to regulation. MT1-MMP-mediated cleavage of GFRAL is a post-translational mechanism that can be modulated by protease activity and trafficking. Additionally, the expression of GFRAL is restricted to specific hindbrain neurons, and its levels may be influenced by developmental and metabolic cues. Therapeutic interventions, such as nanobodies, provide exogenous negative regulation by sequestering GDF15. Feedback loops involving systemic energy status may also adjust the strength of negative regulation, ensuring appropriate appetite control.

Cancer cachexia is a devastating syndrome characterized by involuntary weight loss, muscle wasting, and reduced quality of life. Elevated GDF15 levels in cancer patients activate GFRAL signaling, leading to appetite suppression and metabolic wasting. Negative regulation of this pathway, for example by the nanobody GB18-06, has been shown to alleviate weight loss and restore physical function in cachexia models. Thus, enhancing negative regulation is a promising therapeutic strategy for cachexia.

In a mouse model of ALS, GDF15-GFRAL signaling drives weight loss and alters lipid metabolism, contributing to disease progression. Negative regulation of this pathway could potentially mitigate metabolic deterioration in ALS. Targeting the pathway may offer symptomatic benefits, though further research is needed to determine if modulating GDF15-GFRAL signaling affects motor neuron degeneration.

Obesity and metabolic syndrome are associated with reduced GDF15-GFRAL signaling, suggesting that insufficient pathway activity may contribute to weight gain. Conversely, excessive negative regulation could exacerbate obesity. Understanding the balance of negative regulators, such as MT1-MMP, may inform therapies for metabolic diseases. However, direct evidence linking negative regulation to obesity in humans is still emerging.

Genome-wide CRISPR knockout screens can identify genes whose loss enhances or suppresses GDF15-GFRAL signaling. For example, knocking out MT1-MMP would be predicted to increase GFRAL surface levels and enhance signaling, confirming its role as a negative regulator. Such screens are powerful for discovering novel negative regulators.

RNA sequencing of hindbrain tissues or GFRAL-expressing cells can reveal changes in gene expression upon pathway activation or inhibition. Proteomics can detect GFRAL cleavage products and quantify GDF15 levels. These methods help map the molecular landscape of negative regulation.

Mouse models with genetic modifications (knockout, knock-in) are essential for measuring food intake, body weight, and lipid metabolism. For instance, GDF15-GFRAL signaling drives weight loss in ALS mice, and interventions can be assessed using metabolic cages.

High-throughput screening of nanobody libraries or small molecules can identify agents that block GDF15-GFRAL interaction. GB18-06 is a prime example of a nanobody that negatively regulates the pathway and alleviates cachexia. Such screens are complemented by structural biology to optimize binding.

Researchers studying negative regulation of GDF15-GFRAL signaling pathway-related genes often need to determine whether a candidate gene is causally involved in modulating the pathway, and to dissect the precise molecular mechanisms. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research, from gene knockout to precise point mutations and knock-in models.

GO:0160145, negative regulation of GDF15-GFRAL signaling pathway, represents a critical control node in energy homeostasis and disease. The pathway's activation by GDF15 drives weight loss and metabolic remodeling, while its negative regulation, through mechanisms such as MT1-MMP-mediated GFRAL cleavage or ligand sequestration, can counteract these effects. Understanding these regulatory processes is essential for developing therapies for cachexia, ALS, and metabolic disorders. CRISPR-based models and EDITGENE's services provide powerful tools to dissect the molecular players and translate findings into clinical applications.